Lei Kang
Peking University First Hospital
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Lei Kang as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 12:03 UTC. Open this list on ClinicalTrials.gov
- Ph1NCT07660939 · GPRC5D Targeted PET/CT Imaging in Plasma Cell DisordersPeking University First Hospital · recruiting · Plasma Cell Disorders, Multiple Myeloma (MM) · principal investigator
- Ph2/Ph3NCT07319897 · 68Ga-BCMA PET/CT in Multiple MyelomaPeking University First Hospital · recruiting · Multiple Myeloma, Multiple Myeloma and Malignant Plasma Cell Neoplasms, Multiple Myeloma and Plasma Cell Neoplasm · principal investigator
- Early Ph1NCT06717113 · A Molecular Probe Targeting BCMA for the Clinical Diagnosis of Multiple MyelomaPeking University First Hospital · recruiting · Multiple Myeloma and Malignant Plasma Cell Neoplasms · study chair
- Early Ph1NCT06385652 · PET Imaging Study of 68Ga-NB381 in Multiple MyelomaPeking University First Hospital · recruiting · Multiple Myeloma · study director
Grants
NIH projects from RePORTER, fetched 2026-11-12 12:03 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 3 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name in multiple myeloma, ranked by citations from NIH iCite, fetched 2026-11-12 12:03 UTC. The ranking covers the 200 most relevant of 6 PubMed records, and a shared surname and initials can bring in a namesake. All 6 on PubMed
- Teclistamab plus Daratumumab in Relapsed or Refractory Multiple Myeloma.N Engl J Med · 202685 citationsRCR 42.5
- Anti-CD19 and anti-BCMA CAR T cell therapy followed by lenalidomide maintenance after autologous stem-cell transplantation for high-risk newly diagnosed multiple myeloma.Am J Hematol · 202282 citationsRCR 5.0
- Phase I trial of bortezomib (PS-341; NSC 681239) and alvocidib (flavopiridol; NSC 649890) in patients with recurrent or refractory B-cell neoplasms.Clin Cancer Res · 201139 citationsRCR 1.0
- Phase I trial of bortezomib (PS-341; NSC 681239) and "nonhybrid" (bolus) infusion schedule of alvocidib (flavopiridol; NSC 649890) in patients with recurrent or refractory indolent B-cell neoplasms.Clin Cancer Res · 201422 citationsRCR 0.6
- 22 citationsRCR 3.8